Hepatic Steatosis Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Artificial Intelligence

被引:0
|
作者
Wang, Xiao-Xiao [1 ]
Song, Yu-Yun [1 ]
Jin, Rui [1 ]
Wang, Zi-Long [1 ]
Li, Xiao-He [1 ]
Yang, Qiang [2 ]
Teng, Xiao [3 ]
Liu, Fang-Fang [4 ]
Wu, Nan [1 ]
Xie, Yan-Di [1 ]
Rao, Hui-Ying [1 ]
Liu, Feng [1 ]
机构
[1] Peking Univ, Peoples Hosp, Beijing Int Cooperat Base Sci & Technol NAFLD Diag, Hepatol Inst,Infect Dis & Hepatol Ctr,Beijing Key, Beijing 100044, Peoples R China
[2] Hangzhou Choutu Technol Co Ltd, Hangzhou 310052, Peoples R China
[3] Histoindex Pte Ltd, Singapore 117674, Singapore
[4] Peking Univ, Peoples Hosp, Dept Pathol, Beijing 100044, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
non-alcoholic fatty liver disease; mouse models; steatosis; second-harmonic generation (SHG)/two-photon-excited fluorescence (TPEF); HIGH-FAT DIET; NONALCOHOLIC STEATOHEPATITIS; FEATURES;
D O I
10.3390/diagnostics14242889
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of fat in the liver, excluding excessive alcohol consumption and other known causes of liver injury. Animal models are often used to explore different pathogenic mechanisms and therapeutic targets of MASLD. The aim of this study is to apply an artificial intelligence (AI) system based on second-harmonic generation (SHG)/two-photon-excited fluorescence (TPEF) technology to automatically assess the dynamic patterns of hepatic steatosis in MASLD mouse models. Methods: We evaluated the characteristics of hepatic steatosis in mouse models of MASLD using AI analysis based on SHG/TPEF images. Six different models of MASLD were induced in C57BL/6 mice by feeding with a western or high-fat diet, with or without fructose in their drinking water, and/or by weekly injections of carbon tetrachloride. Results: Body weight, serum lipids, and liver enzyme markers increased at 8 and 16 weeks in each model compared to baseline. Steatosis grade showed a steady upward trend. However, the non-alcoholic steatohepatitis (NASH) Clinical Research Network (CRN) histological scoring method detected no significant difference between 8 and 16 weeks. In contrast, AI analysis was able to quantify dynamic changes in the area, number, and size of hepatic steatosis automatically and objectively, making it more suitable for preclinical MASLD animal experiments. Conclusions: AI recognition technology may be a new tool for the accurate diagnosis of steatosis in MASLD, providing a more precise and objective method for evaluating steatosis in preclinical murine MASLD models under various experimental and treatment conditions.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [22] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [23] Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
    Ryu, Gina
    Yoon, Eileen Laurel
    Kim, Wankyu
    Jun, Dae Won
    DIAGNOSTICS, 2025, 15 (03)
  • [24] From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
    Bruno Basil
    Blessing K. Myke-Mbata
    Onyinye E. Eze
    Augustine U. Akubue
    Clinical Diabetes and Endocrinology, 10 (1):
  • [25] Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
    Takahashi, Yoshihisa
    Dungubat, Erdenetsogt
    Kusano, Hiroyuki
    Fukusato, Toshio
    BIOMEDICINES, 2023, 11 (10)
  • [26] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [27] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [28] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [29] Predicting hepatic steatosis degree in metabolic dysfunction-associated steatotic liver disease using obesity and lipid-related indices
    Forouzesh, Paniz
    Kheirouri, Sorayya
    Alizadeh, Mohammad
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [30] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255